TL/DR –
The article highlights three companies leveraging artificial intelligence (AI) in the healthcare sector. SoundHound AI’s Q1 2026 revenue rose 52% YoY to $44.2 million, and the company projects $350M-$400M in 2027 revenue after the LivePerson deal closes. Meanwhile, Evolent Health reaffirmed its 2026 revenue to be between $2.4B-$2.6B with an expected growth of 30%, and C3.ai’s Q3 FY2026 revenue of $53.3M was down 46.1% YoY. Despite different risk factors like margin pressure and restructuring outcomes, these companies are seizing the opportunity to use AI to reduce labor costs in healthcare systems.
Investing in the Future: AI in Healthcare
Healthcare systems are actively using agentic AI to reduce labor costs, creating a demand for low-cost automation platforms. Three companies, SoundHound AI (SOUN), Evolent Health (EVH), and C3.ai (AI), are seizing this opportunity despite the inherent execution risks related to margin pressure, contract performance, and restructuring outcomes.
SoundHound AI (NASDAQ: SOUN)
SoundHound AI offers voice and agentic AI software used by various industries, including healthcare. The company’s Q1 2026 revenue increased 52% YoY to $44.20 million. They’re projecting a revenue of $350 million to $400 million in 2027 post the LivePerson deal closure. However, potential investors must consider possible margin pressure due to the integration of LivePerson.
Evolent Health (NYSE: EVH)
Evolent Health uses AI and machine learning for specialty care management. Despite missing revenue expectations in Q1 2026, the company confirmed a revenue projection of $2.40 billion to $2.60 billion in 2026. However, investors should note the increased medical expense ratio, which could impact margins.
C3.ai (NYSE: AI)
C3.ai offers enterprise AI applications, including those used in healthcare. However, Q3 FY2026 saw a 46.1% YoY decline in revenue. The company is implementing restructuring measures, but the process has sparked an investor fraud investigation. Therefore, C3.ai poses the highest risk among the three.
Investors seeking affordable entry into the agentic AI market must carefully consider the unique execution risks associated with each company. Thorough due diligence on guidance, cash reserves, and competitive positioning is key before investing in any of these companies.
Looking for more investment opportunities? An analyst who correctly predicted NVIDIA’s success in 2010 has just named his top 10 AI stocks for 2026.
—
Read More Health & Wellness News ; US News